A Single Centre Study Comparing Continuous Interstitial Fluid Lactate Detection to Standard Measurements of Lactate in Patients Undergoing Elective Coronary Artery Bypass Graft Surgery and/or Valve Replacement.
NCT ID: NCT06602336
Last Updated: 2026-01-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
50 participants
INTERVENTIONAL
2025-05-20
2026-05-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This study will take place at Barts Hospital with patients having planned coronary artery bypass graft (CABG) and/or replacement valve surgery. Participants will wear the sensors on their upper arm, during which the sensors will continuously measure lactate levels. Participants will also have hourly blood samples taken.
In the future, the data from this new device will be used to train computer algorithms to provide quick responses that help manage a patient\'s condition, improving future medical care and technology.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Utility of the Superior Vena Cava Collapsibility Index (SVC-CI) to Predict Fluid Responsiveness in Patients With Coronary Artery Disease Undergoing Surgical Revascularization
NCT06645327
Home Electrocardiogram (ECG) Monitoring After Heart Transplantation
NCT01365806
Thoracic Epidural Reduces Risks of Increased Left Ventricular Mass Index During Coronary Artery Bypass Graft Surgery
NCT03719248
Assessment of Plasma Lactate in Non-cardiac Surgery Monitoring by Transthoracic Echocardiography
NCT03103373
Cardiac Output Monitoring With Estimated Continuous Cardiac Output (esCCO) vs. Transpulmonary Thermodilution (TPTD)
NCT02352324
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The research nurse or doctor will meet with the patient to explain the study and check the following:
Pre-screening: The research nurse, who may also be part of the patient\'s direct care team, will look at the records for patients who are attending St Bartholomew's hospital for cardiac surgery for grafts and/or valve replacement.
Informed Consent: If the patient is eligible, and would like to take part in the study, the research nurse or doctor will ask the patient to sign a consent form indicating their willingness to participate in the study.
Screening: The research nurse or doctor will collect demographic information from the patient and ensure the patient meets the study's inclusion and exclusion criteria.
Sensor Application: Up to 5 days pre-surgery, the research nurse will place two lactate sensors on the patient's arm. The sensor has a 24 hour warm-up period prior to continuously measuring the patient's lactate levels.
Pre-Surgery Admission: The research nurse will gather details about the patient's medical history and current medications. The patient will have their blood pressure, heart rate, respiratory rate, weight, and height measured, and an ECG performed. Baseline blood samples will be collected as per the standard of care pre-CABG and/or valve surgery.
CABG and/or replacement valve surgery: The patient will then undergo their planned CABG and/or replacement valve surgery as usual.
Blood Sampling: The patient will have hourly blood samples taken through the tubes inserted for their surgery for up to 14 hours to compare with the sensor readings. These samples will include 12 arterial lactate, 12 central venous lactate, and 12 venous troponin samples. Hourly measurements of the patient's blood pressure, heart rate, and respiratory rate will be taken, and any medication changes will be noted.
Sensor Removal: Up to 48 hours post-surgery, the sensors will be removed, and the patient's skin will be checked for any changes, like a rash. The patient will also have their blood pressure, heart rate, and respiratory rate measured, and an ECG performed. Any changes to the patient's medication will be noted.
Follow-Up: The study team will monitor the patient for up to 24 hours after the sensor is removed or until the patient is discharged from the hospital (whichever is earlier). The study team will note any medication changes, measure the patient's blood pressure, heart rate, and respiratory rate, and perform an ECG.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Investigational Lactate Device
Continuous interstitial fluid lactate monitoring using the Abbott Investigational Lactate Device
Continuous Lactate Monitoring Device
Continuous interstitial fluid lactate monitoring using the Abbott Investigational Lactate Device.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Continuous Lactate Monitoring Device
Continuous interstitial fluid lactate monitoring using the Abbott Investigational Lactate Device.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* ≥18 to ≤ 90 years old
* Successful surgery as defined by the below criteria (which will be recorded in the eCRF):
* Operative Success: The successful completion of coronary artery bypass grafting (CABG) and/or valve insertion with grafts and/or valves
* Absence of the following complications:
* Significant bleeding requiring reoperation
* Evidence of major life-changing stroke
Exclusion Criteria
* Recent acute coronary syndrome (within 4 weeks of planned consent date)
* Heart failure with EF less than 35% (from TTE or CT from past 6 months - if both available lower value will be used).
* Chronic severe renal failure (estimated eGFR less than 30 mL/min/1.73m2 by the MDRD formula recorded at time of consent)
* Severe anaemia (Hb less than 10 recorded at time of consent)
* Known or suspected allergies to medical grade silicone adhesives
* Pre-existing skin condition on the upper arm where the device would be applied, including recent burns/ scalds, open wounds or clinically significant skin lesions.
* Patients with implanted medical devices such as pacemakers or other CLMs
* Severe liver cirrhosis (≥ stage III)
* Lymphoedema or pitting oedema at the time of consent
* Pregnancy
* History of ongoing malignant disease
* Hypoalbuminaemia (less than 35 g/L recorded at time of consent)
* Those lacking capacity to consent or are deemed vulnerable adults
* Unable to speak English
18 Years
90 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Queen Mary University of London
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Prof Anthony Mathur
Role: STUDY_CHAIR
Queen Mary University of London
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Barts Health
London, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
346076
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.